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WHAT DO WE KNOW?
Liggins and Howie in a landmark study in 1972 reported a decrease in respiratory distress syndrome (RDS) in premature infants whose mothers received antenatal corticosteroids. 3 Numerous studies have been published which support this finding as well as the findings of a decrease in intraventricular hemorrhage (IVH) and neonatal mortality.l.2,4-9 The consensus panel from the first NIH conference on antenatal corticosteroids in 1994 concluded that "antenatal corticosteroid therapy for fetal maturation reduees mortality, RDS, and IVH in premature infants." The second NIH consensus conference in 2000 reafiirmed these conclusions. Thus it would seem reasonable to eonclude that the use of antenatal corticosteroids for all pregnant women between 24 and 34 weeks' gestation at risk of preterm delivery within 7 days and in whom there is no contraindication has become the "norm" or more importantly, "the standard of care."
The optimal benefits are derived when the baby is delivered within 7 days of maternal corticosteroid adrninistration).1,2 It is also generally accepted that either betamethasone (two doses of 12 mg I.M. 24 hours apart) or dexamethasone (four doses of 6 mg I.M. 12 hours apart) are efiicacious in reducing RDS and neonatal mortality.
WHAT IS STill CONTROVERSIAl?
There is little question that the single most controversial issue surrounding the use of antenatal corticosteroids for fetal maturation is the efiicacy and most importantly, the safety, of repeat courses of corticosteroids especially with regards to weekly repeat courses.
This controversy tends to center more on safety issues than on the efiicacy of sueh therapy. Much of the data surrounding the safety issue of antenatal corticosteroids is derived from animal studies which have suggested potential deleterious effects from repeat courses on various fetal organ systems, growth, and neurodevelopment. 2 ,10 Whether or not these data derived from animal studies can be applied to the human fetus remains to be determined.
Human data on repeat courses of corticosteroids (mostly derived from retrospective or observational studies) is less convincing with some studies reporting adverse fetal effects such as decreases in birth weight and head circurnference as well as an actual increase in neonatal mortality without proved benefit. ll -13 Others have found possible benefits and no su eh adverse associations. 14 -16 In the first published randornized prospective study (blinded and placebo controlled) comparing single versus multiple weekly courses of antenatal corticosteroids, Guinn and associates found neither an increase nor a decrease in neonatal morbidity.17 These authors also found no significant decrease in birth weight or head circumference. Moreover, there was a lack of improved efiicacy with repeat courses.
There are several other ongoing randornized clinical trials (RCT) comparing single versus repeat courses of antenatal cortieosteroids. The RCT from the NIH Maternal Fetal Medicine Units Network was recently stopped and as of the time of this editorial, the results have not been presented or published. One other area of long-standing controversy is the use of antenatal corticosteroids in the presence of premature rupture of the fetal membranes (PROM). The major concern with this latter scenario is the potential for an increased risk of maternal and fetal infection. Although much of the data on corticosteroids and PROM is derived from subgroup analysis of larger studies on antenatal corticosteroids in general, the authors of a recent meta-analysis derived from 15 controlled trials and containing over 1400 women with PROM, concluded that antenatal corticosteroids in this setting did reduce neonatal morbidity without a significant increase in the risk of maternalor neonatal infection. 1H The use of antenatal corticosteroids in the setting of PROM is aIso supported by the 2002 Committee Opinion (number 273) of the Ameriean College of Obstetrieians and Gynecologists. 19 
WHAT DO WE NOT KNOW?
Although much is known about the efiicacy and safety of antenatal corticosteroids for fetal maturation (especially for single course therapy), there remain many unanswered questions regarding this unique matemal therapy for fetal/neonatal benefit. No doubt many of our colleagues would argue against the need and feasibility of further steroid trials or research. However, one distinct advantage of being asked to write an editorial is the opportunity to express one's opinion and it is the authors' opinion that much can still be learned and gained from corticosteroid research. One important area which has not been adequately studied is the so-called "rescue approach" to corticosteroid therapy. In this approach, another course of corticosteroids is given at a later date when delivery is felt to be imminent and when the interval from the initial course has been greater than 7 days. Equally important if arescue dose is given, what should the dose be? Is there any potentiation from the initial dose via induction of various molecular mechanisms so that less could be given, thus resulting in less fetal exposure? How fur out from the initial course can a smaller dose of corticosteroids be given to still be effective? Are there risks with the "rescue approach"? Is there a "subgroup" of pregnancies that would benefit from repeat courses of corticosteroids, especially if shown that a smaller repeat dose could be used? Is there a difference in the severity of morbidity with repeat courses of steroids? For example, in the weli-done study by Guinn and associates, significandy fewer newboms delivered at 24 to 27 weeks had composite morbidity if their mothers received weekly courses of corticosteroids. 17 This difference was not significant if composite morbidity was stratified by gestational age at randomization, as opposed to delivery. There was also less severe RDS in the weekly steroid group. Another very important unanswered question is whether there is any significant difference between dexamethasone and betamethasone with regards to either efficacy or safety? Many clinicians and hospitals pref er dexamethasone over betamethasone because of economic issues and because of the occasional difficulty in obtaining betamethasone; whereas others pref er betamethasone because of the ease of administration (i.e., requiring only two doses as opposed to four doses). Although RCTs comparing these two stereoisomers are lacking, there have been worrisome reports from both animal and human studies of possible different effects of the two steroids. For example in one study in mice, dexamethasone treated animals had decreased memory while betamethasone treated animals had enhanced memory compared with controls. 20 In another study involving sheep, betamethasone was associated with preterm labor and alteration in fetal heart rate. 1U Probably the most worrisome findings were reported by Baud and associates who noted that matemal treatrnent with dexamethasone resulted in an increase in periventricular leukomalacia (PVL) while betamethasone was associated with a decrease in PVL. 21 This finding has been suggested by others as weIl. 9 ,22 Even given the lack of enthusiasm for further corticosteroid trials, the latter question would seem to "beg an answer" and would seem to be a worthwhile project to invest time and economie resources. It would also seem that given the mounting concern of possible adverse effects of corticosteroids, it Gilstrap would seem reasonable to attempt to use the smallest possible dose of corticosteroid that would be effective in preventing RDS. Finally, it is hoped that in vitro studies using cell and tissue cultures, as weIl as weli-designed animal studies will help elucidate the mechanism of action of corticosteroids on various organ systerns.
